Murat Hakkı Yarar

Murat Hakkı Yarar

Auto-generated profile, based on publicly available information

Murat Hakkı Yarar

UNIVERSITY OF HEALTH SCIENCES, İSTANBUL ÜMRANİYE HEALTH RESEARCH CENTER, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF MEDICAL GENETICS

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
SCSengul Caglayan
Sengul Caglayan
GMGizem Mardinoğlu
Gizem Mardinoğlu
MYMurat Hakkı Yarar
Murat Hakkı Yarar
KUKadir Ulu
Kadir Ulu
TCTaner Coşkuner
Taner Coşkuner
BSBetul Sozeri
Betul Sozeri

4 November 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MEMetin Eser
Metin Eser
GHGulam Hekimoglu
Gulam Hekimoglu
MYMurat Hakki Yarar
Murat Hakki Yarar
SCSezin Canbek
Sezin Canbek
MÖMelike Özçelik
Melike Özçelik
Lung cancer remains a significant health challenge, characterized by aberrant tissue growth within the pulmonary system. Early carcinogenic events often involve genomic instability and the emergence of a mutator phenotype. In this study, we aimed to explore the mutator phenotype in 89 patients diagnosed with non-small-cell lung cancer (NSCLC). RNA isolation from formalin-fixed paraffin-embedded (FFPE) tissue samples was performed using the Promega ReliaPrep RNA Miniprep System, facilitating gene amplification relevant to cancer through the Archer® FusionPlexComprehensiveThyroid and Lung (CTL) kit. Next-generation sequencing (NGS) on the Illumina NextSeq platform enabled comprehensive analysis of target areas. Utilizing Archer Analysis software, secondary analyses involving data cleansing, alignment, and variant/fusion identification were executed against the human reference genome hg19 (GRCh37). Expression patterns were visualized using HeatMap graphics. Our findings revealed a notable presence of KRAS gene mutations in approximately 20% of NSCLC patients. Among these mutations, the G12C variant was predominant at 50%, followed by G12V and G12D variants at 11.2% each. Notably, patients harboring the G12C variant responded favorably to sotorasib medication. These results underscore the importance of mutational profiling and targeted therapeutic approaches in managing NSCLC, particularly highlighting the promising efficacy of sotorasib in G12C-mutated cases.


16 December 2025 in Black Sea Journal of Health Science
Verified
Journal Article
Closed access
MEMetin Eser
Metin Eser
GHGulam Hekimoglu
Gulam Hekimoglu
MYMurat Hakkı Yarar
Murat Hakkı Yarar
GAGülçiçek Ayrancı
Gülçiçek Ayrancı
EKESRA KELES
ESRA KELES
MÖMelike Özçelik
Melike Özçelik
High-grade serous ovarian cancer (HGSOC) is an aggressive form of epithelial carcinoma associated with poor prognosis. Although relatively uncommon, mutations in the BRCA1/2 genes are linked to HGSOC. Poly(ADP-ribose) polymerase inhibitors (PARPi) have been approved for treating patients with BRCA1/2 mutations, significantly improving outcomes for this subgroup. To assess the prevalence of BRCA1/2 mutations in high-grade serous ovarian cancer (HGSOC) patients who tested negative for germline BRCA1/2 mutations and to evaluate the potential implications of tumor-based genetic testing for expanding PARPi therapy eligibility. 75 patients who underwent Somatic BRCA1/BRCA2 Next Generation Sequencing (NGS) and positive for somatic but negative for germline BRCA1/2 mutations were selected and included in the study. Tumor tissue samples, either formalin-fixed paraffin-embedded or fresh, were analyzed using NGS to detect somatic mutations in BRCA1/2 genes. The study also examined variants of uncertain significance (VUS) within these genes. Pathogenic somatic mutations in the BRCA1/2 genes were identified in 8 patients (11%), while a VUS was detected in 1 patient (1%). Variant mutations c.135-8A>G, c.1084G>T (p.Glu362Ter), c.5095C>T (p.Arg1699Trp), and c.3756_3759del (p.Ser1253fs) were found in the BRCA1 gene, while c.5073dup (p.Trp1692fs), c.426-1G>A, c.3751_3752insA (p.Thr1251AsnfsTer14), and c.771_775del (p.Asn257fs) were found in the BRCA2 gene. Our study highlights the importance of expanding the availability of PARPi therapy to patients with somatic BRCA1/2 mutations and providing targeted therapy to guide patients with high-grade ovarian serous cancer. As treatments evolve, integrating comprehensive genetic testing into clinical practice is vital to improving care.

1 June 2021 in Endocrine and Metabolic Science
Verified
Journal Article
Open access
SKSavas Volkan Kisioglu
Savas Volkan Kisioglu
YGYasemin Emur Gunay
Yasemin Emur Gunay
MYMurat Hakkı Yarar
Murat Hakkı Yarar
MKMustafa KOCAK
Mustafa KOCAK

1 January 2024 in OSMANGAZİ JOURNAL OF MEDICINE
Verified
Journal Article
Closed access
SCSezin Canbek
Sezin Canbek
MYMurat Hakkı Yarar
Murat Hakkı Yarar
MEMetin Eser
Metin Eser
HYHakan Yazan
Hakan Yazan
Cystic fibrosis is an autosomal recessive disease caused by pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The spectrum and frequencies of CFTR mutations vary among populations. As a result of continuous migration around the world, the frequency of CF variants may change and is still unclear in some geographies. We aimed to define the CFTR gene variants we observed as a result of our single-center experience. This research assessed the outcomes of 353 patients who underwent next-generation sequencing to identify variations in the CFTR gene. Variants classified as clinically uncertain significance, likely pathogenic or pathogenic detected in patients with pre-diagnosis of cystic fibrosis who underwent genetic testing were included in the evaluation. The variants detected in the vast majority of cases were comparable to those found in other populations. However, some variants showed significant differences in allele frequencies when compared to European and Asian populations. Mutations were detected in 25.2% of cases. This dataset revealed that the most common mutations in patients presenting to our center were c.2991G>C, c.2856G>C, c.1545_1546delTA, c.1521_1523 del and c.202A>G. This research presents data on CFTR variations to determine the frequency of CF in the Istanbul province of our nation and to identify additional frequently occurring pathogenic variants that are currently unknown. This kind of research has the potential to facilitate the creation of a localized strategy for maximizing healthcare provision for individuals with CF.